Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Total Liabilities: 2017-2024

Historic Total Liabilities for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $51.5 million.

  • Cidara Therapeutics' Total Liabilities rose 106.13% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.3 million, marking a year-over-year increase of 106.13%. This contributed to the annual value of $51.5 million for FY2024, which is 31.57% down from last year.
  • As of FY2024, Cidara Therapeutics' Total Liabilities stood at $51.5 million, which was down 31.57% from $75.2 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Total Liabilities peaked at $75.2 million during FY2023, and registered a low of $49.7 million during FY2020.
  • Its 3-year average for Total Liabilities is $62.9 million, with a median of $61.9 million in 2022.
  • Per our database at Business Quant, Cidara Therapeutics' Total Liabilities surged by 59.63% in 2020 and then plummeted by 31.57% in 2024.
  • Cidara Therapeutics' Total Liabilities (Yearly) stood at $49.7 million in 2020, then increased by 8.13% to $53.8 million in 2021, then rose by 15.21% to $61.9 million in 2022, then climbed by 21.50% to $75.2 million in 2023, then tumbled by 31.57% to $51.5 million in 2024.